Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious DiseasePipeline Analysis

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536156

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1536156

Impetigo Drugs

PUBLISHED:
PAGES: 193 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Impetigo Drugs Market to Reach US$2.1 Billion by 2030

The global market for Impetigo Drugs estimated at US$1.5 Billion in the year 2023, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2023-2030. Fusidane Drug, one of the segments analyzed in the report, is expected to record a 5.1% CAGR and reach US$883.5 Million by the end of the analysis period. Growth in the Quinolones Drug segment is estimated at 3.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$422.1 Million While China is Forecast to Grow at 7.5% CAGR

The Impetigo Drugs market in the U.S. is estimated at US$422.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$432.8 Million by the year 2030 trailing a CAGR of 7.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 4.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.7% CAGR.

Global Impetigo Drugs Market - Key Trends and Drivers Summarized

Impetigo is a highly contagious bacterial skin infection that primarily affects infants and young children, though it can occur in individuals of any age. The infection is caused by Staphylococcus aureus or Streptococcus pyogenes and is characterized by red sores that quickly rupture, ooze for a few days, and then form a yellowish-brown crust. Impetigo is typically treated with antibiotics, either topically applied directly to the sores or taken orally in more severe cases. The most commonly prescribed topical antibiotics include mupirocin and fusidic acid, while oral antibiotics such as penicillin, erythromycin, and cephalexin are used for more extensive infections. The choice of treatment depends on the severity of the infection, the patient's age, and any underlying health conditions.

Recent advancements in the development of impetigo drugs have focused on improving the efficacy and reducing the resistance of bacterial strains to existing treatments. Researchers are working on new formulations and delivery systems to enhance the penetration and effectiveness of topical antibiotics. Moreover, there is growing interest in combination therapies that utilize both topical and oral antibiotics to combat severe or resistant infections. Advances in molecular biology and genomics have also enabled the identification of novel antibiotic targets, leading to the development of new drug candidates that can potentially overcome resistance mechanisms. These innovations are critical as the prevalence of antibiotic-resistant bacteria continues to rise, posing significant challenges to effective impetigo management.

The growth in the impetigo drugs market is driven by several factors. The increasing incidence of impetigo, particularly in regions with warm, humid climates and crowded living conditions, has heightened the demand for effective treatments. Technological advancements in drug delivery systems, such as liposomal and nanoparticle formulations, have expanded the addressable market by offering improved drug stability and targeted delivery. The rise in antibiotic resistance has spurred the development of new antibiotics and combination therapies, which are crucial for maintaining the efficacy of impetigo treatments. Additionally, greater awareness of impetigo symptoms and the importance of early treatment among parents and healthcare providers is driving market demand. The expansion of healthcare infrastructure in emerging markets, along with increased healthcare spending, is also contributing to market growth. Furthermore, regulatory support for the development of new antibiotics and expedited approval processes for critical drugs are facilitating the entry of new treatments into the market. Collectively, these factors are fostering a dynamic and rapidly evolving market for impetigo drugs.

Select Competitors (Total 86 Featured) -

  • Grupo Ferrer Internacional, S.A.
  • GSK Plc
  • Laboratorios Ojer Pharma S.L.
  • LEO Pharma A/S
  • Lytix Biopharma AS
  • Medimetriks Pharmaceuticals, Inc.
  • NovaBay Pharmaceuticals, Inc.
  • Novartis AG
  • UNION therapeutics A/S
  • Vaxcyte;
Show more
Product Code: MCP26854

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Impetigo Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Impetigo Spurs Demand for Effective Treatments
    • Technological Advancements in Drug Delivery Propel Growth
    • Development of Novel Antibiotics Expands Addressable Market Opportunity
    • Increasing Antibiotic Resistance Strengthens Business Case for New Treatments
    • Here's How Combination Therapies Generate New Market Opportunities
    • Advances in Molecular Biology and Genomics Propel Innovation in Drug Development
    • Growing Healthcare Spending in Emerging Markets Sustains Growth
    • Increasing Number of Clinical Trials Validating Efficacy and Safety of New Drugs Drive Market Confidence
    • Economic Burden of Skin Infections Strengthens Business Case for Effective Solutions
    • Here's the Story: Impact of Pediatric and Geriatric Populations on Market Demand
    • Rising Adoption of Topical Antibiotics Drives Market Growth
    • Expansion of Online Pharmacies Expands Access to Impetigo Drugs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Impetigo Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Impetigo Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Fusidane Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Fusidane Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Quinolones Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Quinolones Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Sulfonamide Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Sulfonamide Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Tetracycline Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Tetracycline Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 23: Canada Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Canada Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Canada 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Japan 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • CHINA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 29: China Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: China Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: China 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Impetigo Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 35: Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: France 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 41: Germany Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Germany Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Germany 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Italy Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Italy 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 47: UK Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: UK Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: UK 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 50: Spain Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Spain Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Spain 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 53: Russia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Russia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Russia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Rest of Europe 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Impetigo Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 65: Australia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Australia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: Australia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • INDIA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 68: India Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: India Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: India 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 71: South Korea Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 72: South Korea Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: South Korea 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Rest of Asia-Pacific Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Impetigo Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 80: Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 83: Argentina Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Argentina Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Argentina 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 86: Brazil Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Brazil Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Brazil 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 89: Mexico Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Mexico Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Mexico 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of Latin America Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Rest of Latin America 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Impetigo Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Impetigo Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 98: Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 101: Iran Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Iran Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Iran 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 104: Israel Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Israel Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: Israel 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Saudi Arabia Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Saudi Arabia 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 110: UAE Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: UAE Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: UAE 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Middle East Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Middle East 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Impetigo Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 116: Africa Recent Past, Current & Future Analysis for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Africa Historic Review for Impetigo Drugs by Drug Type - Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 118: Africa 16-Year Perspective for Impetigo Drugs by Drug Type - Percentage Breakdown of Value Sales for Fusidane Drug, Quinolones Drug, Sulfonamide Drug, Tetracycline Drug and Other Drug Types for the Years 2014, 2024 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!